PDF Cover

Transcatheter Devices Market

The market for Transcatheter Devices was estimated at $11.1 billion in 2025; it is anticipated to increase to $19.0 billion by 2030, with projections indicating growth to around $32.5 billion by 2035.

Report ID:DS1801062
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Transcatheter Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Transcatheter Devices Market Outlook

Revenue, 2025

$11.1B

Forecast, 2035

$32.5B

CAGR, 2026 - 2035

11.3%

The Transcatheter Devices industry revenue is expected to be around $11.1 billion in 2026 and expected to showcase growth with 11.3% CAGR between 2026 and 2035. Increasing preference for minimally invasive treatments that lower the cost of treatments, the length of hospital stays and the rate of complications underlines the key role of Transcatheter Devices in modern healthcare. In the field of medical devices, cardiology and oncology treatments combined comprised 80.3% of demand. This shows how crucial it is for the industry of oncology intervention and cardiology to provide treatments for cancer and heart disease. The market for Transcatheter Devices was led by Replacement Devices which reached $5.38 billion in sales in the year 2025. This is a reflection of the strong interest shown by patients in advanced implants including transcatheter heart valves used to treat structural heart disease. Advances in technology driving the development of Transcatheter Devices are underpinned by clinical trials. As a result, these devices can be used in more situations and get licensed quicker. This is leading to their greater adoption in both existing and developing healthcare systems. A broad range of catheter based treatments is covered by transcatheter devices, such as heart valves inserted via catheter, stent grafts, embolization systems and catheters. These systems are used to gain access to tissues which are diseased via the skin. Patients with high or moderate risk profiles are especially drawn to technology which includes faster recovery times, smaller access points, precise device placement and compatibility with radiological procedures. Among its applications are the treatment of heart disease, vascular conditions and tumours, particularly those situated in the brain. The growth in demand is currently driven by minimally invasive surgery becoming more common among younger patients and those with lower risks. Other drivers for growth include the incorporation of digital and robotic technology to improve device navigation and the adoption of more advanced drugs and materials. A further key factor is the emphasis placed on the outcomes of treatment. This information will be crucial for the long term market penetration of Transcatheter Devices.

Transcatheter Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Transcatheter Devices Market Outlook

Market Key Insights

  • The market for devices inserted through catheters is predicted to reach $32.5 billion in 2035 from $11.1 billion in 2025. At a compound annual growth rate of 11.3%, the sector has seen considerable increases in demand, mainly for treatments of cardiovascular issues and the correction of congenital heart defects, and in vascular access provision.

  • Leading manufacturers of heart valve systems include Abbott, Edwards Lifesciences Corporation and Boston Scientific Corporation, the latter of which are responsible for the markets competitive landscape.

  • The Transcatheter Devices market in the United States and Germany is expected to show growth at a Compound Annual Growth Rate of 8.2% to 11.9% over the period 2025 to 2030.

  • These markets Brazil, Australia and India are expected to see the most growth with an annual growth rate of between 10.8% and 14.1%.

  • The trend of moving towards less invasive treatments is expected to give a considerable boost to the development of the transcatheter devices market and could increase its value by $2 billion by the year 2030.

  • The global market for transcatheter devices is expected to rise by $21.3 billion over the period 2025 to 2035. The sector dealing with oncology and neurological applications is projected to capture a bigger share of this market.

  • The demand for minimally invasive surgical procedures is on the increase; in conjunction with advances in technology which allow for catheter based interventions, the transcatheter devices industry is set to increase by a factor of 192.2 between 2020 and 2030.

transcatheter devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Transcatheter Devices - Country Share Analysis

Opportunities in the Transcatheter Devices

The embolization and occlusion devices sector of the transcatheter sector is also growing rapidly, due to increasing medical interventions in the Asia Pacific region and other developing region's in oncology and neurovascular treatments. Growing medical investment is helping to make it possible for more hospitals to use minimally invasive embolisation for controlling tumours and preventing strokes. Between 2025 and 2030, the sector is anticipated to rise from $3.13 billion to $4.86 billion, growing at 9.2% CAGR. The neurovascular embolization segment is expected to experience the greatest growth.

Growth Opportunities in North America and Asia-Pacific

Cardiovascular applications lead Transcatheter Devices in North America, in which both structural heart interventions and transcatheter heart valves have been the main revenue producers. Neurovascular solutions have been used more in centres for the treatment of strokes. Opportunities for the company in the future exist in the expansion of the treatments target market to lower risk patients who are younger, investing in equipment for hospitals that will carry out minimally invasive surgery, and combining the technology with the use of medical imaging and robotics. The medical devices industry is fiercely competitive, with multinational firms holding onto their market position with their extensive portfolios of catheter based interventions. The smaller companies which are new and innovative are aiming for market share by targeting region's such as embolization, the left atrial appendage closure and in the field of peripheral access. The region is driven by high volumes of treatments in cardiology procedures, the availability of reimbursement for neurovascular and structural heart treatments and a considerable clinical evidence base. Several hospital networks in the region are consolidating and prefer to partner with companies which are able to offer medical devices as well as services.
The cardiovascular treatments employing catheters in the Asia Pacific region are the applications where Transcatheter Devices are most required at present. The regions with large cities are witnessing an increase in demand for catheter based cancer therapy and for interventional treatments for neurological disorders. Opportunities exist in developing heart valves, stents and embolisation products, which have had the cost engineering taken out, for regions with limited budgets. This could also include training for doctors in these region's and partnerships between the public and private sectors to allow more people to undergo minimally invasive operations in hospitals other than the best. The global market is characterised by the presence of major international companies alongside rapidly expanding regional manufacturers, with the latter competing mainly on the basis of price and customisation. This is in contrast to major international firms which differentiate their products with reference to clinical data, reliability and complex interventions involving catheters. The region is experiencing growth due to an increase in cath labs, along with an increase in the number of people suffering from heart and cancer problems. Furthermore, governments are putting money into the latest medical facilities and there is a growing acceptance by patients and clinicians of non invasive treatments that reduce recovery time and surgery risks.

Market Dynamics and Supply Chain

01

Driver: Increasing Demand for Minimally Invasive Procedures, and Rise in Cardiovascular Diseases

Over the recent years, the healthcare sector has also seen a significant shift from traditional open surgeries to less invasive procedures. This trend has also notably fueled the growth of Transcatheter devices market as they are also primarily used for minimally invasive treatments. The rising occurrence of diseases on a global scale has also led to a growing need for safe and efficient treatment methods that are also in demand continuously. Transcatheter devices have also shown their effectiveness, in managing a range of heart conditions. Are also well suited to fulfill this requirement which propels the growth of their market.
The rise of Transcatheter treatments such as Transcatheter aortic valve replacement and Transcatheter mitral valve repair has also played a significant role in boosting the popularity and utilization of these devices, within the healthcare community. Continuous advancements and research efforts focused on improving the effectiveness and safety of these devices further drive market growth.
02

Restraint: High Cost of Devices

The steep costs of these cutting edge tools pose a financial challenge in emerging markets and can impede the widespread use of transcatheter devices in the industry. This has an effect, on the markets expansion by restricting the availability and affordability of these pioneering healthcare remedies to numerous prospective patients globally.
03

Opportunity: Rapidly expanding transcatheter replacement devices market for structural heart disease in aging global cardiac populations and Accelerating adoption of transcatheter repair devices for high-surgical-risk mitral patients in advanced healthcare systems

There is growing demand for the transcatheter devices industry as a result of interventional cardiologys shift towards minimal invasive treatments for structural heart conditions. A significant role has been assumed by replacement devices with this in mind, notably the transcatheter heart valves. These medical devices are of great benefit to elderly patients with a heightened surgical risk who cannot have open heart surgery. The market is projected to rise from $5.38 billion to $9.18 billion by the year 2030; this represents a compound annual growth rate of 11.3%. Devices to replace the aortic and mitral valves will be responsible for the majority of the growth in revenue generated by heart valve replacements worldwide.
Treatment of mitral regurgitation and tricuspid regurgitation is being transformed through the use of transcatheter mitral and tricuspid repair systems. The trend in cardiology is towards less invasive procedures, particularly for patients who have a high surgical risk. As a result, there is growing need for annuloplasty based transcatheter devices and edge to edge repair systems. The sector is predicted to grow from $2.63 billion in 2025 to $4.97 billion by 2030, with the fastest CAGR of 13.61% during this period. Mitral repair through a catheter will experience the strongest growth, largely due to collaborations between imaging centres, heart doctors and the manufacturers of catheters.
04

Challenge: Risks and Complications

Transcatheter techniques are considered advanced and less invasive; however they do come with risks and possible complications such as issues, with blood vessels, device errors and the chance of a stroke occurring during the procedure. These risks sometimes discourage both patients and healthcare providers from choosing these procedures which in turn limits the growth of transcatheter device market.

Supply Chain Landscape

1

Cardiovascular Components

DSM BiomedicalGore MedicalTeleflex
2

Transcatheter Devices Manufacturing

Edwards Lifesciences CorporationAbbottMedtronic
3

Minimally Invasive Distribution

Cardinal HealthOwens & MinorMedline Industries
4

Structural Heart Applications

HospitalsCardiac catheterization laboratoriesAmbulatory surgical centers
Transcatheter Devices - Supply Chain

Use Cases of Transcatheter Devices in Cardiovascular Treatment & Congenital Heart Defect Correction

Cardiovascular Treatment : Transcatheter devices like heart valves play a role in treating cardiovascular conditions by offering a minimally invasive alternative to open heart surgery for patients who may not only be suitable for the latter option due to its faster recovery time and lower trauma impact benefits they provide compared to traditional methods of treatment. Companies such as Medtronic and Edwards Lifesciences are, at the forefront of driving advancements in this field.
Congenital Heart Defect Correction : Transcatheter devices are also used in correcting heart defects in children specifically and are an alternative, to the traditional open heart surgery methods to lower risks and improve patient comfort levels; Boston Scientific Corporation plays a significant role in this region.
Vascular Access Provision : An exciting application of transcatheter technology is to create access for hemodialysis in individuals, with severe kidney disease nearing the end stage of renal failure. These cutting edge devices increase device longevity. Reduce the occurrence of complications ultimately enhancing patient well being. Friedrich Medical and Asahi Intecc are widely recognized for their state of the art transcatheter devices designed for access.

Recent Developments

The use of devices is experiencing significant growth in the global medical equipment industry due to technological advancements. Recent progress in this field has greatly enhanced the effectiveness. Minimized the risks of transcatheter surgeries – a trend that is significantly shaping the market landscape. An emerging trend that stands out is the increasing emphasis, on invasive treatment options.

December 2024 : Medtronic broadened its range of products by introducing the Next Generation Transcatheter Pacing System. This new system aims to improve outcomes by simplifying procedures.
October 2024 : Boston Scientific has been given the light by the FDA for its latest Valve Centric Transcatheter Heart Valve. This innovative valve aims to provide tailored treatments, for individuals suffering from valvar conditions.
July 2024 : Abbott Laboratories introduced a cutting edge transcatheter valve called AimFitTM to revolutionize the treatment of patients, with mitral regurgitation.

Impact of Industry Transitions on the Transcatheter Devices Market

As a core segment of the Medical Device industry, the Transcatheter Devices market develops in line with broader industry shifts. Over recent years, transitions such as Transition to Minimally Invasive Procedures and undefined have redefined priorities across the Medical Device sector, influencing how the Transcatheter Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition to Minimally Invasive Procedures

The trend towards minimally invasive procedures is driving the development of the transcatheter devices market. Catheter based treatments are increasingly preferred over traditional open heart surgery in cardiology. The trend in the cardiology devices market is being influenced by the fact that catheter based technologies cause less trauma, allow patients to be discharged from hospital quicker and enable quicker recovery times. As a result, the market is predicted to rise by a further $2 billion by 2030. The competitive landscape is undergoing a significant transformation, necessitating the enhancement of R&D in the development of advanced transcatheter technologies, improved product delivery and durability and the expansion of uses for interventional cardiology. With a growing emphasis on better results for patients and a need for healthcare cost savings, major hospitals are adopting Transcatheter devices. These are used as an alternative to conventional open heart surgery and are key to their long term growth through innovation.